Clinical Trial Update: Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing airway inflammation effects of FlutiForm pMDI at low and high doses in adults with mild to moderate asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm (fluticasone propionate/formoterol)

Snippet

Sponsor: Mundipharma Research Limited | Conditions: Asthma | Phase 2 | Status: COMPLETED